Osteolabs has announced osteolabsUK, a joint venture with medical business specialist Christopher Brain, designed to boost access to OsteoTest, a CE-marked diagnostic used in the early detection of osteoperosis.
Located in Marlow, osteolabs UK will work alongside osteoperosis professionals to seek to ensure that UK patients have ready access to OsteoTest, which has already been successfully launched in several EU countries, including Germany.
Within the UK, osteoperosis is responsible for more than 500,000 hospitalisations per year, at a cost of over £4.4 billion. OsteoTest can both detect osteoperosis and monitory therapy for the disease.
Christopher Brain, who will serve as Managing Director for osteolabs UK, commented: “I am thrilled to establish and to lead this joint venture together with osteolabs, a leading player for early detection of osteoporosis. This is a devastating disease affecting millions of patients per year.”
Dr Stefan Kloth, osteolabs CEO, added: “We are very happy to have partnered with Chris who is a very experienced Medtech commercial leader with many years of business experience. Together, we see a tremendous opportunity to bring our well established OsteoTest to the UK market.”
Dr. Bernd Buchholz, Minister of Economic Affairs of the Federal State of Schleswig-Holstein, said: "osteolabs is a perfect example of an innovative player in the state who is courageously paving its way and expanding the business despite the ongoing pandemic.”
“I am very pleased to see that know-how from Schleswig-Holstein is now being applied more and more internationally through partnerships and now the formation of a joint venture with a leading UK partner.”